The debate over physical activity and strength training in GLP-1 treatment has moved from polite health-club chatter to hard economic argument, after new multinational research suggested that weight-loss drugs work best when the prescription pad and the squat rack are not treated as distant relatives.
GLP-1 medications have become one of the defining health stories of the decade, altering the conversation around obesity treatment with the sort of speed usually reserved for runaway golf buggies on wet fairways. But a new white paper backed by ukactive and international health and fitness leaders argues that the long-term value of these drugs depends heavily on what happens after the injection.
The white paper, From Weight Loss to Lasting Value: Structured Exercise and the Economics of GLP-1 Therapy, was developed by FTI Consulting’s Center for Healthcare Economics and Policy. It compares GLP-1 therapy used on its own with GLP-1 therapy combined with structured exercise across Australia, Canada, New Zealand, the United Kingdom and the United States.
Its conclusion is hardly a tap-in, but it is clear: structured exercise, particularly strength training, could help patients keep more weight off, preserve muscle, maintain mobility and reduce the expensive health complications that tend to arrive later, usually with a bill tucked under one arm.
Why Exercise Is Becoming Central To GLP-1 Treatment
The study lands at a delicate moment for governments, health systems and insurers. GLP-1 drugs are changing obesity care, but they also raise awkward questions about coverage, reimbursement, prescribing policy and long-term patient support.
The new research argues that medication alone should not be treated as the full answer. Weight loss may be the headline figure, but bodies are not spreadsheets. Losing weight without protecting muscle and strength, and the victory can start looking suspiciously fragile.
According to the analysis, adding structured exercise to GLP-1 therapy can help patients preserve muscle during weight loss, maintain strength, mobility and bone health, keep more weight off over time, reduce weight regain after stopping medication and lower the risk of costly health events later on.
That makes physical activity and strength training in GLP-1 treatment not a decorative extra, but a practical part of obesity care.
The Economic Case: Billions In Potential Value
The study modelled the economic and societal value of combining regular exercise with GLP-1 therapy over 10 and 30 years. The numbers are large enough to make even a Treasury official blink.
In the United Kingdom, the combined approach is estimated to generate around £2.7bn in economic and societal value over 10 years, with a 164% return on investment. Over 30 years, that rises to £13bn and a 717% return on investment.
In the United States, the estimate is US$120bn over 10 years with a 496% return on investment, rising to US$393bn and 1,572% over 30 years.
Australia is estimated at A$182m over 10 years and A$1.4bn over 30 years. Canada comes in at C$3.5bn over 10 years and C$17.9bn over 30 years. New Zealand is estimated at NZ$51m over 10 years and NZ$592m over 30 years.
The research does not pretend that exercise is a magic wand. Anyone who has ever tried to reintroduce themselves to a leg press after a long absence knows better. But it does present structured exercise as a serious health intervention with measurable economic consequences.
A Call For Fitness To Be Built Into Obesity Care
ukactive, the Health & Fitness Association, the HFA Foundation, AUSactive, Exercise New Zealand and the Fitness Industry Council of Canada are now calling for policymakers, payers and healthcare systems to integrate structured exercise into GLP-1 treatment pathways.
That means recognising structured exercise, including strength training, as an essential part of obesity care. It also means embedding exercise support into GLP-1 care models, building referral pathways between healthcare providers and qualified exercise professionals, and improving patient access to fitness facilities and trained support.
Just as importantly, the groups want outcomes to be measured beyond weight loss alone. The scale may be useful, but it is a blunt instrument. Strength, function, mobility, bone health, weight maintenance and long-term economic value all tell a richer story.
The call follows a recent joint position statement signed by the participating fitness industry groups, the World Obesity Federation and the World Federation of the Sporting Goods Industry, which emphasised the need for physical activity and nutrition to sit at the centre of systems supporting the global roll-out of obesity medications.
ukactive: The Bill For Inaction Cannot Keep Growing
Cameron Saunders, CEO of ukactive, said: “GLP-1 medications have the potential to be genuinely transformative, but to really achieve this potential fully they must be combined with structured exercise.
“This research shows what could be at stake if they are not: £2.7bn in avoidable costs to the UK health system over the next 10 years alone.
“Our members are ready to be delivery partners – we have the facilities, the professionals and programmes to make it happen at scale.
“The evidence is clear and the bill for inaction is one that health systems cannot keep picking up.”
That last line carries the weight of the report. Health systems are already grappling with rising obesity, chronic disease, physical inactivity and escalating costs. GLP-1 treatment may offer a powerful tool, but the research suggests it works better as part of a wider model that helps people build durable health, not just lose kilos in the short term.
Strength Training And Sustainable Weight Loss
Greta Wagner, President and CEO (Interim) of the Health & Fitness Association and President of the HFA Foundation, said: “GLP-1 medications are rapidly changing obesity treatment, but weight loss alone is not the full measure of success.
“The health and fitness industry has long known that lasting wellness requires more than a number on a scale; it requires strength, function, and sustainable healthy life habits.
“This research confirms that exercise, especially strength training, helps patients sustain the benefits of GLP-1 treatment over time. It sends a clear message that exercise belongs at the centre of GLP-1 care.”
That is the crux. GLP-1 drugs may help people lose weight, but long-term health is built in less glamorous places: repeated sessions, sensible progression, qualified coaching, resistance work, movement habits and the unshowy business of turning treatment into a life that can actually be lived.
For policymakers, the argument is economic. For clinicians, it is clinical. For patients, it is deeply practical. A smaller number on the scale is one thing. Being stronger, steadier, more mobile and less likely to regain weight is quite another.
The emerging message is not anti-medication. It is anti-half-measure. If GLP-1 therapy is to fulfil its promise, the future of obesity care may need fewer silos and more joined-up thinking — ideally with a well-supervised strength session somewhere in the middle.
